Lilly Eyes Fast-Track Approval for Oral Weight-Loss Drug in U.S.

Eli Lilly said its experimental oral weight-loss pill may qualify for accelerated approval under a new U.S. regulatory programme designed to speed access to high-impact therapies. The oral candidate is seen as a critical pillar in Lilly’s long-term obesity strategy, complementing the success of its injectable GLP-1 products. Securing a fast-track review could shorten the approval timeline significantly, potentially allowing earlier entry into a market expected to exceed $100 billion by 2030. The pill is aimed at improving patient convenience and adherence, addressing barriers associated with injectable treatments. Lilly highlighted strong clinical performance to date and expects that regulatory incentives for metabolic-disease therapies could support faster market authorisation. The company continues to expand manufacturing capacity and global access plans as demand for obesity treatments accelerates across regions.